This meeting has been canceled.

Biotechnology companies are investing hundreds of millions of dollars to bring innovative products to the medical marketplace.  But earning FDA or EMA approval doesn’t guarantee market success, or even market access.  

As financial pressures affect health care authorities and payers worldwide, and this includes the commercial insurers, Medicare, Medicaid and others in the United States, they are demanding that biotech companies share evidence of value as a precondition for coverage and reimbursement.  Successful companies understand this and are planning and implementing their market access strategies early in product development.  In parallel with generating the data needed for the FDA and EMA, these innovative companies are also developing a value proposition supported by the appropriate evidence. 

• What characterizes a successful strategy to achieve market access through evidence? 
• How does it take into account the needs of different stakeholders: providers, payers and patients? 
• What evidence is expected by those stakeholders, and how is that evidence compiled?
• How is the plan implemented given the evolving marketplace?
• How will the plan help you gain market access and market success?

 These and other questions will be addressed by a panel representing biotechnology firms, payers and researchers, who will share their understanding through case studies of success and failure.  

The session is intended for those responsible for Market Access, Business Development, Investment, Partnership, Medical Affairs, Clinical, and Marketing.   

Speakers for this symposium include:

• Clark Paramore, Senior Research Scientist at United BioSource Corporation
• Audra Boscoe, PhD, Director of Health Economics and Outcomes Research at Genzyme Corp.
• Stephen Boccuzzi, PhD, MBA, Vice President, Advanced Clinical Science and Research at Medco Health Solutions
• Lorrie Carr, Senior Director of US Market Access at Millennium: The Takeda Oncology Company

Clark Paramore is a Senior Research Scientist in Health Economics at United BioSource Corporation, based in Lexington, MA.  Mr. Paramore has conducted pharmacoeconomic studies for biotechnology and pharmaceutical companies for 15 years, including economic modeling, retrospective database analyses, and literature reviews.  In the past five years, Mr. Paramore has consulted with companies looking to develop evidence generation strategies to develop and support the value proposition for their pipeline products. He holds a MSPH in Health Policy from the University of North Carolina-Chapel Hill.

Audra Boscoe is Director of Health Economics and Outcomes Research at Genzyme, where she is responsible for building and demonstrating evidence of value for products in the multiple sclerosis franchise.  Her role includes overseeing the collection and evaluation of health economics and quality of life data from clinical trials, real world data analyses, cost-effectiveness and budget impact modeling, global value dossier development, and related activities to support market access.   She has 12 years of experience in the industry.  Prior to joining Genzyme she worked at AstraZeneca and United BioSource Corporation.  She holds an MPH from Yale University and a PhD in Health Services Research from Johns Hopkins Bloomberg School of Public Health.

Stephen Boccuzzi, PhD, MBA, currently holds the position of Vice President, Advanced Clinical Science and Research at Medco Health Solutions.  In this role he is responsible for identifying and developing strategic research and process of care collaborations between Medco and various public, academic and health technology organizations. Dr. Boccuzzi is a tenured health services researcher with a diversity of clinical, research and business expertise in the areas of drug development, technology assessment, effectiveness research and evidence based medicine.  He has extensive experience in controlled clinical trials, outcomes research, health economics, health care & informatics consulting and business development across the academic, pharmaceutical and commercial sectors. He is a Fellow of the American College of Cardiology and American Heart Association and holds several adjunct faculty & teaching positions.  He has authored numerous peer-reviewed journals and sits on the editorial review boards of several medical journals.

Lorrie Carr is currently the Senior Director of US Market Access at Millennium: The Takeda Oncology Company where she and her team are responsible for working cross-functionally with development teams, HEOR, Marketing, and Global Medical Affairs in order to develop the value proposition for marketed and pipeline products in the US. Prior to Millennium Ms. Carr was the Director of Managed Markets Marketing for Primary Care and Specialty products at Schering-Plough (now Merck) and she held other roles within managed care and physician practice management organizations.    Ms. Carr holds a degree in Business from Columbia College and an MBA from the Isenberg School of Management.